-
1 month ago | 
onlinelibrary.wiley.com | Adeolu Oladunjoye |Alan Swann |Thomas R. Kosten |Michelle Patriquin
Peter Barr PhD VA New York Harbor Healthcare System, Brooklyn, New York, USA Department of Psychiatry and Behavioral Sciences, SUNY Downstate Health Sciences University, Brooklyn, New York, USA Institute for Genomics in Health (IGH), SUNY Downstate Health Sciences University, Brooklyn, New York, USA Department of Epidemiology and Biostatistics, School of Public Health, SUNY Downstate Health Sciences University, Brooklyn, New York, USA Department of Community Health Sciences, School of Public...
-
Mar 8, 2025 | 
onlinelibrary.wiley.com | Thomas R. Kosten |Coreen Domingo
INTRODUCTION Proceedings of the 35th Annual Meeting & Scientific Symposium Thomas R. Kosten MD, Thomas R. Kosten MD Editor-in-Chief Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, Texas, USASearch for more papers by this authorCoreen B. Domingo DrPH, MSW, Coreen B. Domingo DrPH, MSW Deputy Editor Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, Texas, USASearch for more papers by this author Thomas R.
-
Dec 10, 2024 | 
psychiatrictimes.com | Heidi Anne Duerr |Thomas R. Kosten
CommentaryArticleDecember 10, 2024Author(s):,Thomas R. Kosten, MD, shares thoughts on the latest schizophrenia genetic model research presented at the meeting. Sharing his thoughts at the 63rd Annual Meeting of the American College of Neuropsychopharmacology, Thomas R. Kosten, MD, member of the Psychiatric Times editorial board, discussed research on the genetic underpinnings of schizophrenia.
-
Dec 9, 2024 | 
psychiatrictimes.com | Heidi Anne Duerr |Thomas R. Kosten
Promising advances are being discussed at the 63rd Annual Meeting of the American College of Neurpsychopharmacology in Phoenix, Arizona. Kosten, a member of the Psychiatric Times editorial board, shared his thoughts on the meeting itself as well as the presentations for promising new targets. Although still early in the meeting, he has already attended several presentations, including the Promising Targets Oral Session.
-
May 6, 2024 | 
ajp.psychiatryonline.org | Thomas R. Kosten
Access content To read the fulltext, please use one of the options below to sign in or purchase access. Personal login Institutional Login Sign in via OpenAthens Register for access Purchase Save for later Item saved, go to cart Not a subscriber? Subscribe Now / Learn MorePsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources.
-
Mar 14, 2024 | 
nature.com | Tim B. Bigdeli |Peter Barr |Jacquelyn L. Meyers |Bryan R. Gorman |David A Nielsen |Hongyu Zhao | +7 more
AbstractPersons diagnosed with schizophrenia (SCZ) or bipolar I disorder (BPI) are at high risk for self-injurious behavior, suicidal ideation, and suicidal behaviors (SB). Characterizing associations between diagnosed health problems, prior pharmacological treatments, and polygenic scores (PGS) has potential to inform risk stratification.
-
Oct 30, 2023 | 
nature.com | Li Wang |Thomas R. Kosten
AbstractChronic low-grade peripheral and central nervous system inflammation may have a role in the pathogenesis of schizophrenia (SCZ). Inhibition of cyclooxygenase-2 (COX2), the arachidonic acid pathway, may inhibit cytokine responses and minimize inflammation. In this study, we added the COX2 inhibitor celecoxib to risperidone monotherapy to examine its efficacy on clinical symptoms and cognitive deficits in drug-naïve first episode (DNFE) SCZ patients.
-
Oct 9, 2023 | 
psychiatrictimes.com | Thomas R. Kosten |Leah Kuntz
The US Food and Drug Administration (FDA) published a new draft guidance to assist in the development of treatments for stimulant use disorders: Stimulant Use Disorders: Developing Drugs for Treatment. This will be the first guide that contains the FDA’s recommendations on the development program and clinical trial design for drugs intended for the treatment of cocaine use disorder, methamphetamine use disorder, and prescription stimulant use disorder.1Thomas R. Kosten, MD, the Jay H.
-
Jul 25, 2023 | 
nature.com | Kai Yuan |Wei Yan |Le Shi |Thomas R. Kosten |Jie Shi |Yanping Bao
AbstractThe increasing number of coronavirus disease 2019 (COVID-19) infections have highlighted the long-term consequences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection called long COVID.
-
Jul 4, 2023 | 
nature.com | Thomas R. Kosten |Zezhi Li
AbstractAlthough many studies have showed abnormal thalamocortical networks in patients with schizophrenia (SCZ), the dynamic functional thalamocortical connectivity of individuals with SCZ and the effect of antipsychotics on this connectivity have not been investigated. Drug-naïve first-episode individuals with SCZ and healthy controls were recruited. Patients were treated with risperidone for 12 weeks. Resting-state functional magnetic resonance imaging was acquired at baseline and week 12.
